Early data presented for a biomarker-guided care of metastatic hormone-sensitive prostate cancer
Positive findings from the CAPTURE and AMPLITUDE trials highlight the importance of early testing patients for BRCA and HRR mutations
Machine learning models predict adverse events and survival in patients receiving immunotherapy
New data supports the use of artificial intelligence for the administration of immune-check inhibitors in solid tumours
Talazoparib plus axitinib show some signs of efficacy in heavily pretreated cancers
Early-phase findings report manageable toxicity when combining the PARP inhibitor with the anti-angiogenesis inhibitor in two cohorts of patients with ovarian and castration-resistant prostate tumours
Novel insights into combination therapy in metastatic castration-resistant prostate cancer
Final survival data from the TALAPRO-2 study support the use of a PARP inhibitor plus an androgen receptor pathway inhibitor
Novel data continue to support the use of perioperative durvalumab with neoadjuvant chemotherapy in bladder cancer
Additional analysis from the NIAGARA study were presented
An oncolytic adenovirus shows promise in inducing immune response in prostate cancer
Early-phase data suggest that intratumour injections of ORCA-010 may convert cold tumours into immunogenic ones
Sacituzumab govitecan failed to improve overall survival in pre-treated urothelial carcinoma
Despite being active in this disease setting, the antibody-drug conjugate was associated to high rates of neutropenic complications
Intravesical system for prolonged delivery of gemcitabine improves outcomes in two forms of bladder cancer
Findings from two studies show high rates of complete remissions in patients with Bacillus Calmette-Guérin unresponsive high-risk non-muscle-invasive bladder cancer and muscle-invasive bladder cancer
Adding durvalumab to neoadjuvant chemotherapy improves survival in muscle-invasive bladder cancer
Practice changing results of event-free survival and overall survival are reported from the NIAGARA study
Mixed results reported for cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer
Final overall survival data from the CONTACT-02 study are negative, but a survival advantage was observed with the novel combination in patients with liver or bone metastasis